Literature DB >> 18485144

Current and future therapy in Alzheimer's disease.

Robert J van Marum1.   

Abstract

Dementia is increasingly being recognized as one of the most important medical problems in the elderly. As most pharmacological research within the field of dementia is focused on Alzheimer's dementia (AD), this review will focus on pharmacological interventions in AD. Most disease-modifying therapies are based on the amyloid hypothesis. In this hypothesis, the pathological accumulation of Abeta in the brain leads to oxidative stress, neuronal destruction and finally the clinical syndrome of AD. Following this hypothesis, secondary prevention of AD can be made by: decreasing the production of Abeta, stimulation of clearance of Abeta formed or prevention of aggregation of Abeta into amyloid plaques. First a short overview on current approved therapies for AD is given. The main part of the review will focus on potential disease-modifying therapies for AD that are currently being studied in phase I to phase III trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485144     DOI: 10.1111/j.1472-8206.2008.00578.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  34 in total

1.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

2.  Do amyloid-lowering strategies work clinically?

Authors:  Rob J van Marum
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

3.  Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.

Authors:  Shiri Stempler; Michal Levy-Sakin; Anat Frydman-Marom; Yaniv Amir; Roni Scherzer-Attali; Ludmila Buzhansky; Ehud Gazit; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-12-17       Impact factor: 3.686

4.  Improving the quality of life in patients with Alzheimer's disease.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2008-08

5.  Activation of 5-HT(2C) receptor promotes the expression of neprilysin in U251 human glioma cells.

Authors:  Xiao-Lu Tian; Lin-Hui Yu; Wen-Qin Li; Yue Hu; Ming Yin; Ze-Jian Wang
Journal:  Cell Mol Neurobiol       Date:  2014-12-02       Impact factor: 5.046

6.  α-Mangostin decreases β-amyloid peptides production via modulation of amyloidogenic pathway.

Authors:  Lan-Xue Zhao; Yan Wang; Ting Liu; Yan-Xia Wang; Hong-Zhuan Chen; Jian-Rong Xu; Yu Qiu
Journal:  CNS Neurosci Ther       Date:  2017-04-21       Impact factor: 5.243

7.  Natural Modulators of Amyloid-Beta Precursor Protein Processing.

Authors:  C Zhang; R E Tanzi
Journal:  Curr Alzheimer Res       Date:  2012-09-13       Impact factor: 3.498

8.  Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.

Authors:  Jacqueline A Vernarelli; J Scott Roberts; Susan Hiraki; Clara A Chen; L Adrienne Cupples; Robert C Green
Journal:  Am J Clin Nutr       Date:  2010-03-10       Impact factor: 7.045

9.  eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer's disease.

Authors:  Andrew Bottley; Nicola M Phillips; Thomas E Webb; Anne E Willis; Keith A Spriggs
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

Review 10.  Memory loss in Alzheimer's disease: implications for development of therapeutics.

Authors:  Carl A Gold; Andrew E Budson
Journal:  Expert Rev Neurother       Date:  2008-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.